You are here
Cordlife is Asia’s largest network of cord blood banks
Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, StemLife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai StemLife. In addition to cord blood, cord lining and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening and newborn metabolic screening.
At Cordlife, our primary commitment revolves around two key areas: ensuring reliable quality and placing you, our valued customer, at the centre of everything we do. Our mission is to make transfusion medicine and biotherapies safe, available, and effective on a global scale. We strive to maintain the highest standards in cord blood banking for your confidence and well-being. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong one of the few private cord blood banks in the world to be accredited by three international standard-setting bodies, and Cordlife India is one of the only two medical laboratories in West Bengal to hold accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement.
Cordlife has processed and stored an nearly 400,000 cord blood, cord lining, and cord tissue stem cell samples.
The Group has made 71 cord blood releases to 18 healthcare institutions in nine different countries, allowing their clients to use their cord blood for transplantation or cellular therapy. Cordlife has also assisted its clients in the release of ten cord lining and cord tissue samples for medical use. All of the samples processed and stored by Cordlife were accepted and successfully used, which is the ultimate validation of the Group’s processing and storage capabilities.
Over the years, the Group has also grown to offer diagnostics and other healthcare services. This has helped to strengthen their position as a leading company focused on protecting the health of mother and child.
The umbilical cord, once discarded as medical waste after childbirth, is a rich source of readily available stem cells for therapies. Cordlife Group is constantly collaborating with credible researchers and partners to help families live healthier, happier, and longer. Cordlife has recently published a study with one of their strategic partners, CellResearch Corporation (CRC), on the superior effects of using their patented culture media to extract and accelerate the growth of mesenchymal stromal cells (MSC) from cryopreserved umbilical cord tissue. The study also discussed the numerous advantages of umbilical cord-derived MSCs in the healing of chronic wounds. As the healthcare industry shifts towards a greater focus on early detection and preventive care, umbilical cord-derived MSCs will play an important role in not only treating diseases but also slowing their progression or even delaying their onset entirely. This collaboration validates Cordlife Group’s commitment to being a part of the future of medicine and healthcare to help people live better lives.